Russo, PatriziaDel Bufalo, AlessandraFini, Massimo2015-04-222015-04-222015-02-101611-2156http://hdl.handle.net/2003/3405710.17877/DE290R-7879The deep-sea habitat is a source of very potent marine-derived agents that may inhibit the growth of human cancer cells “in vitro” and “in vivo”. Salinosporamide-A, Marizomib, by Salinispora species is a proteasome inhibitor with promising anticancer activity (Phase I/II trials). Different deep-sea-derived drugs are under preclinical evaluation. Cancer is a complex disease that may be represented by network medicine. A simple consequence is the change of the concept of target entity from a single protein to a whole molecular pathway and or cellular network. Deep-sea-derived drugs fit well to this new concept.enEXCLI Journal ; Vol. 14, 2015deep-sea-derived drugscancersystems medicinenetworktherapypreclinical studiesclinical studies610article (journal)